[go: up one dir, main page]

GB2169265B - Pack for medicament - Google Patents

Pack for medicament

Info

Publication number
GB2169265B
GB2169265B GB8602264A GB8602264A GB2169265B GB 2169265 B GB2169265 B GB 2169265B GB 8602264 A GB8602264 A GB 8602264A GB 8602264 A GB8602264 A GB 8602264A GB 2169265 B GB2169265 B GB 2169265B
Authority
GB
United Kingdom
Prior art keywords
medicament
pack
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB8602264A
Other versions
GB8602264D0 (en
GB2169265A (en
Inventor
Robert Edward Newell
Robert Alexander Fitzsimmons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB838314307A external-priority patent/GB8314307D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB8602264A priority Critical patent/GB2169265B/en
Publication of GB8602264D0 publication Critical patent/GB8602264D0/en
Publication of GB2169265A publication Critical patent/GB2169265A/en
Application granted granted Critical
Publication of GB2169265B publication Critical patent/GB2169265B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0035—Piercing means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/60—General characteristics of the apparatus with identification means
    • A61M2205/6063—Optical identification systems
    • A61M2205/6081—Colour codes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
GB8602264A 1982-10-08 1986-01-30 Pack for medicament Expired GB2169265B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB8602264A GB2169265B (en) 1982-10-08 1986-01-30 Pack for medicament

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8228887 1982-10-08
GB838314307A GB8314307D0 (en) 1983-05-24 1983-05-24 Medical administration devices
GB8602264A GB2169265B (en) 1982-10-08 1986-01-30 Pack for medicament

Publications (3)

Publication Number Publication Date
GB8602264D0 GB8602264D0 (en) 1986-03-05
GB2169265A GB2169265A (en) 1986-07-09
GB2169265B true GB2169265B (en) 1987-08-12

Family

ID=27261782

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8602264A Expired GB2169265B (en) 1982-10-08 1986-01-30 Pack for medicament

Country Status (1)

Country Link
GB (1) GB2169265B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
US6792945B2 (en) 1990-03-02 2004-09-21 Glaxo Group Limited Inhalation device
US7225808B2 (en) 1990-03-02 2007-06-05 Glaxo Group Limited Inhalation device

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9012870D0 (en) * 1990-06-08 1990-08-01 Glaxo Group Ltd Device
GB9016789D0 (en) * 1990-07-31 1990-09-12 Lilly Industries Ltd Medicament administering devices
US5042472A (en) * 1990-10-15 1991-08-27 Merck & Co., Inc. Powder inhaler device
US5337740A (en) * 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
DE19647947A1 (en) * 1996-11-20 1998-05-28 Pfeiffer Erich Gmbh & Co Kg Discharge device for media
SE9900188D0 (en) * 1999-01-22 1999-01-22 Astra Ab Dispensing device
US6810872B1 (en) 1999-12-10 2004-11-02 Unisia Jecs Corporation Inhalant medicator
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
KR100889426B1 (en) 2000-08-05 2009-03-23 글락소 그룹 리미티드 6.alpha., 9.alpha.-difluoro-17.alpha .- '(2-furanylcarboxyl) oxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo as anti-inflammatory -Androst-1,4-diene-17-carbothioic acid S-fluoromethyl ester
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE381537T1 (en) 2001-03-22 2008-01-15 Glaxo Group Ltd FORMANILIDE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS
AU2002253342B2 (en) 2001-04-30 2007-01-04 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
US20040244794A1 (en) * 2001-08-09 2004-12-09 Richards David Hugh Inhalation device with a pharmaceutical composition
AU2002326026B2 (en) 2001-09-14 2005-04-28 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
ATE381535T1 (en) 2002-04-25 2008-01-15 Glaxo Group Ltd PHENETHANOLAMINE DERIVATIVES
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AU2003286143A1 (en) 2002-10-28 2004-05-13 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
PE20050250A1 (en) 2003-07-17 2005-04-08 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLIN MUSCARINAL RECEPTORS
TW200811172A (en) 2003-10-14 2008-03-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AR046114A1 (en) 2003-10-17 2005-11-23 Glaxo Group Ltd COMPOSITE OF 8- AZONIABICICLO (3.2.1) OCTOBER, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES MEDIATED BY MUSCARINIC ACETILCOLINE RECEPTORS AND USE OF THE COMPOUND TO PREPARE SUCH COMPOSITION
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
US7384946B2 (en) 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
AU2005227733A1 (en) 2004-04-02 2005-10-13 Glaxo Group Limited Chemical process and new crystalline form
PE20060259A1 (en) 2004-04-27 2006-03-25 Glaxo Group Ltd QUINUCLIDINE COMPOUNDS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR
JP2007537261A (en) 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド Muscarinic acetylcholine receptor antagonist
EP3199164B1 (en) 2005-02-10 2020-03-18 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
PE20061193A1 (en) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVATIVES OF 3,4-DIHYDROPYRIMIDO [4,5-d] PYRIMIDIN-2- [1H] -0NA AS KINASE INHIBITORS p38
UY29440A1 (en) 2005-03-25 2006-10-02 Glaxo Group Ltd NEW COMPOUNDS
EP1937068A4 (en) 2005-08-18 2010-08-04 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
PE20081889A1 (en) 2007-03-23 2009-03-05 Smithkline Beecham Corp INDOL CARBOXAMIDES AS INHIBITORS OF IKK2
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
PT3578169T (en) 2009-02-26 2024-07-29 Glaxo Group Ltd Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
TW201111392A (en) 2009-06-16 2011-04-01 Schering Corp Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2611423B2 (en) 2010-08-31 2022-09-21 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP3461474B1 (en) 2010-08-31 2020-11-11 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
US9297813B2 (en) 2010-11-11 2016-03-29 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
SG11201406274VA (en) 2012-04-27 2014-11-27 Glaxo Group Ltd Novel compounds
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
SG11201503697TA (en) 2012-11-28 2015-06-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
WO2016142426A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
EP3766878B1 (en) 2015-06-15 2022-03-16 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
CN107709306A (en) 2015-06-15 2018-02-16 葛兰素史密斯克莱知识产权发展有限公司 NRF2 modulator
CA2988338C (en) 2015-06-15 2024-05-14 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
TW201722965A (en) 2015-08-16 2017-07-01 葛蘭素史密斯克藍智慧財產發展有限公司 Compounds for use in antibacterial applications
JP2018529744A (en) 2015-10-06 2018-10-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Arylcyclohexylpyrazoles as NRF2 regulators
EP3359532A1 (en) 2015-10-06 2018-08-15 GlaxoSmithKline Intellectual Property Development Limited Biaryl pyrazoles as nrf2 regulators
CN109790116B (en) 2016-09-20 2022-10-28 葛兰素史密斯克莱知识产权（第2 号）有限公司 TRPV4 antagonists
EP3515889A1 (en) 2016-09-20 2019-07-31 GlaxoSmithKline Intellectual Property (No. 2) Limited Trpv4 antagonists
TW201825458A (en) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 TRPV 4 antagonists
KR20190088404A (en) 2016-12-06 2019-07-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 3- (2,3-dihydro-1H-inden-5-yl) propanoic acid derivatives and their use as NRF2 regulators
US20200071310A1 (en) 2016-12-12 2020-03-05 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
US20200031820A1 (en) 2016-12-12 2020-01-30 Glsxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
US11078216B2 (en) 2016-12-14 2021-08-03 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as NRF2 activators
US20220002272A1 (en) 2016-12-14 2022-01-06 Glaxosmithkline Intellectual Property Development Limited Bisaryl lactams as nrf2 activators
JP2020502123A (en) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Bisaryl heterocycles as NRF2 activators
US11028099B2 (en) 2016-12-15 2021-06-08 Glaxosmithkline Intellectual Property Development Limited NRF2 activators
JP2020502152A (en) 2016-12-15 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ether-linked triazoles as NRF2 activators
PL3615545T3 (en) 2017-04-24 2022-01-10 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
WO2019116231A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
US20210177861A1 (en) 2017-12-11 2021-06-17 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
GB201720989D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN111868063B (en) 2018-01-17 2023-08-01 葛兰素史克知识产权开发有限公司 PI4KIII beta inhibitors
EP3796906A1 (en) 2018-05-23 2021-03-31 GlaxoSmithKline Intellectual Property Management Limited Indanes as nrf2 activators
WO2020023813A1 (en) 2018-07-27 2020-01-30 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
CN113286793B (en) 2018-09-10 2024-04-05 共结晶制药公司 Inhibitors of influenza virus replication of pyrrolopyrazines and pyridotriazines
PT3866778T (en) 2018-10-17 2023-02-28 Cocrystal Pharma Inc Combinations of inhibitors of influenza virus replication
BR112021009254A2 (en) 2018-11-13 2021-08-10 Cocrystal Pharma, Inc. formulations for influenza therapeutics
EP3887355A1 (en) 2018-11-26 2021-10-06 Cocrystal Pharma, Inc. Inhibitors of influenza virus replication
GB201908536D0 (en) 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds
WO2021188620A1 (en) 2020-03-17 2021-09-23 Cocrystal Pharma Inc. Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
IL297069A (en) 2020-04-10 2022-12-01 Cocrystal Pharma Inc Inhibitors of norovirus and coronavirus replication
EP4138884A1 (en) 2020-04-20 2023-03-01 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
KR20240055745A (en) 2021-08-03 2024-04-29 코크리스탈 파마, 아이엔씨. coronavirus inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB516834A (en) * 1937-12-23 1940-01-12 Charles Alexandre Nicolle Improvements in or relating to packaging
US3038282A (en) * 1960-07-05 1962-06-12 American Cyanamid Co Capsules of soft plastic containing granules
CH385718A (en) * 1961-11-04 1964-12-15 Bodet Jean Method and device for packaging solid articles of small volume, and assembly obtained by this method
CH411232A (en) * 1963-11-12 1966-04-15 Ciba Geigy Drug packaging
GB1387954A (en) * 1973-05-08 1975-03-19 Miles Lab Insufflator
CH581992A5 (en) * 1975-08-15 1976-11-30 Laib Jakob C
US4342395A (en) * 1981-02-02 1982-08-03 Brown James B Liquid dispensing unit and method of manufacture thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
US6792945B2 (en) 1990-03-02 2004-09-21 Glaxo Group Limited Inhalation device
US7225808B2 (en) 1990-03-02 2007-06-05 Glaxo Group Limited Inhalation device
US7389775B2 (en) 1990-03-02 2008-06-24 Glaxo Group Limited Inhalation device

Also Published As

Publication number Publication date
GB8602264D0 (en) 1986-03-05
GB2169265A (en) 1986-07-09

Similar Documents

Publication Publication Date Title
GB2169265B (en) Pack for medicament
GB2138403B (en) Unit portion pack
AU584535B2 (en) Medicament - containing pack
DE3175224D1 (en) Sterile pack
DE3375458D1 (en) Syringes
GB8301435D0 (en) Skinpackaged pouches
GB8411259D0 (en) Medicinal agent
GB2117350B (en) Boil-in-bag pouch
DE3372979D1 (en) Packaging
GB2118832B (en) Pouch packs for tobacco
ZA84846B (en) Blister pack
GB8332269D0 (en) Pharmaceutical compounds
GB2119754B (en) Blister packs
GB8329359D0 (en) Film pack
GB8326204D0 (en) Packaging arrangement
GB2130480B (en) Back packs
GB2132974B (en) Meat stock-forming pack
IL67768A0 (en) Medicaments containing l-methionine
IL64993A0 (en) Terminal-post for batteries
IL80468A (en) Medicament-containing pack
IL80468A0 (en) Medicament-containing pack
KE3861A (en) Medicament-containing pack
AU89653S (en) Blister pack
GB8306994D0 (en) Heat-sealing
IL65945A0 (en) Improved back pack

Legal Events

Date Code Title Description
727B Case decided by the comptroller ** specification amended (sect. 27/1977)
711A Proceeding under section 117(1) patents act 1977
PE20 Patent expired after termination of 20 years

Effective date: 20031006